Business Description
Charles River Laboratories International Inc
NAICS : 541714
SIC : 8732
251 Ballardvale Street, Wilmington, MA, USA, 01887
Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 1.29 | |||||
| Debt-to-EBITDA | 3.92 | |||||
| Interest Coverage | 16.16 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.49 | |||||
| Beneish M-Score | -2.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.2 | |||||
| 3-Year EBITDA Growth Rate | 15.5 | |||||
| 3-Year EPS without NRI Growth Rate | 18.3 | |||||
| 3-Year FCF Growth Rate | 19 | |||||
| 3-Year Book Growth Rate | 22.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 15.93 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 11.73 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.16 | |||||
| 9-Day RSI | 54.28 | |||||
| 14-Day RSI | 52.77 | |||||
| 6-1 Month Momentum % | -34.28 | |||||
| 12-1 Month Momentum % | -46.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.33 | |||||
| Quick Ratio | 1.08 | |||||
| Cash Ratio | 0.19 | |||||
| Days Inventory | 33.28 | |||||
| Days Sales Outstanding | 50.53 | |||||
| Days Payable | 27.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.36 | |||||
| Operating Margin % | 18.03 | |||||
| Net Margin % | 12.02 | |||||
| ROE % | 17.68 | |||||
| ROA % | 6.26 | |||||
| ROIC % | 8.62 | |||||
| ROC (Joel Greenblatt) % | 36.65 | |||||
| ROCE % | 9.58 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 27.03 | |||||
| Forward PE Ratio | 20.04 | |||||
| PE Ratio without NRI | 27.03 | |||||
| Shiller PE Ratio | 47.4 | |||||
| Price-to-Owner-Earnings | 26.81 | |||||
| PEG Ratio | 1.74 | |||||
| PS Ratio | 3.25 | |||||
| PB Ratio | 4.48 | |||||
| Price-to-Free-Cash-Flow | 35.46 | |||||
| Price-to-Operating-Cash-Flow | 18.28 | |||||
| EV-to-EBIT | 25.84 | |||||
| EV-to-Forward-EBIT | 19.56 | |||||
| EV-to-EBITDA | 17.3 | |||||
| EV-to-Forward-EBITDA | 15.1 | |||||
| EV-to-Revenue | 4.08 | |||||
| EV-to-Forward-Revenue | 3.73 | |||||
| EV-to-FCF | 44.51 | |||||
| Price-to-Projected-FCF | 1.68 | |||||
| Price-to-DCF (Earnings Based) | 1.07 | |||||
| Price-to-DCF (FCF Based) | 1.66 | |||||
| Price-to-Median-PS-Value | 1.19 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.72 | |||||
| Earnings Yield (Greenblatt) % | 3.87 | |||||
| Forward Rate of Return (Yacktman) % | 18.7 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:CRL
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,688.047 | ||
| EPS (TTM) ($) | 8.62 | ||
| Beta | 1.34 | ||
| Volatility % | 37.89 | ||
| 14-Day RSI | 52.77 | ||
| 14-Day ATR ($) | 9.682583 | ||
| 20-Day SMA ($) | 231.627 | ||
| 12-1 Month Momentum % | -46.66 | ||
| 52-Week Range ($) | 203.37 - 460.21 | ||
| Shares Outstanding (Mil) | 50.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Charles River Laboratories International Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||